Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Other Non-Current Liabilities (2021 - 2025)

LifeStance Health (LFST) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $68000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 77.99% to $68000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $68000.0, a 77.99% decrease, with the full-year FY2025 number at $68000.0, down 77.99% from a year prior.
  • Other Non-Current Liabilities was $68000.0 for Q4 2025 at LifeStance Health, down from $105000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $67.0 million in Q3 2022 to a low of $68000.0 in Q4 2025.
  • A 5-year average of $13.3 million and a median of $3.7 million in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 192.49% in 2022, then tumbled 96.22% in 2024.
  • LifeStance Health's Other Non-Current Liabilities stood at $17.4 million in 2021, then increased by 2.26% to $17.8 million in 2022, then plummeted by 54.17% to $8.2 million in 2023, then crashed by 96.22% to $309000.0 in 2024, then plummeted by 77.99% to $68000.0 in 2025.
  • Per Business Quant, the three most recent readings for LFST's Other Non-Current Liabilities are $68000.0 (Q4 2025), $105000.0 (Q3 2025), and $182000.0 (Q2 2025).